Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab

Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells

1999 • 1,218 citations

Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature.

1994 • 626 citations

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

1997 • 531 citations

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation

2000 • 525 citations

Quantifying the Frequency of Alloreactive T Cells In Vivo: New Answers to an Old Question

2001 • 519 citations

Role of Antibody to S100 Protein in Diagnostic Pathology

1983 • 442 citations

ELIMINATION OF GRAFT-VERSUS-HOST DISEASE BY IN-VITRO DEPLETION OF ALLOREACTIVE LYMPHOCYTES WITH A MONOCLONAL RAT ANTI-HUMAN LYMPHOCYTE ANTIBODY (CAMPATH-1)

1984 • 436 citations

Human peripheral blood contains two distinct lineages of dendritic cells

1999 • 380 citations

Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement

1983 • 365 citations

The CAMPATH‐1 antigen (CDw52)

1990 • 334 citations

A CD1a+/CD11c+ Subset of Human Blood Dendritic Cells Is a Direct Precursor of Langerhans Cells

1999 • 334 citations

Humanised monoclonal antibody therapy for rheumatoid arthritis

1992 • 316 citations

Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.

1986 • 298 citations

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.

1997 • 210 citations

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

1993 • 208 citations

Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft Rejection

1998 • 207 citations

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

1994 • 186 citations

Identification of hematopoietic progenitors of macrophages and dendritic Langerhans cells (DL-CFU) in human bone marrow and peripheral blood

1990 • 186 citations

CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells

2000 • 167 citations

Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia

1997 • 133 citations

Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation

2003 • 133 citations

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM–CAMPATH conditioning: an effective regimen with low procedure‐related toxicity

2000 • 74 citations

The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia

2000 • 65 citations

CAMPATH-1M—PROPHYLACTIC USE AFTER KIDNEY TRANSPLANTATION

1989 • 63 citations

Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement

1983 • 16 citations